Health insurance for cancer treatment can be less overwhelming by taking some simple steps.
Survivor and advocate Florence Kurttila describes her key takeaways from the 2019 Gastrointestinal Cancers Symposium.
Laredo, Texas, was ASCO President Dr. Bertagnolli’s latest stop in her ASCO in the Community tour. These visits are focused on understanding and addressing the barriers that prevent people from receiving quality cancer care. Local medical oncologist Dr. Eduardo Miranda shares what patients, caregivers, and health care providers in his community had to say.
ASCO has released the results of its second National Cancer Opinion Survey. Learn how Americans view alternative treatments, which Americans worry most about paying for and getting cancer care, and whether Americans feel people with cancer should have access to opioids.
Opioid Use in Cancer Care and the Burden of Cancer-Related Costs: Research from the 2018 Quality Care Symposium
Research highlights from the meeting include new details on the use of opioids in cancer care and the burdens of the cost of care.
ASCO Annual Meeting 2018: Geriatric Assessment Improves Communication, Racial and Gender Differences in Cancer Treatment, and a Comparison of Cancer Treatment Costs
Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights include the effects of geriatric assessment on patient-doctor communication, treatments for advanced prostate cancer that may work better in black men, the possibility that women are undertreated for head and neck cancer, and a comparison of treatment costs for colorectal cancer between the U.S. and Canada.
In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
A cancer diagnosis is stressful, and the discussion of the treatment plan starts quickly. But a cancer diagnosis affects everything and involves more than just the treatment plan. Here are 3 things to consider.